A Single-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis

Trial Profile

A Single-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs Icotinib (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions
  • Sponsors Betta Pharmaceuticals Co Ltd
  • Most Recent Events

    • 12 Jul 2017 Status changed from recruiting to completed.
    • 10 Jun 2017 Biomarkers information updated
    • 03 Jan 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top